Activity

Clinical Utility of Treating Patients with Compounded "Bioidentical Hormone Replacement Therapy"


Type: Consensus Study
Topics: Biomedical and Health Research, Public Health, Quality and Patient Safety
Board: Board on Health Sciences Policy

Activity Description

 


 An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine (National Academies) will conduct a study to assess the clinical utility of treating patients with compounded BHRT drug products. The committee will: 

Review the current and historic use of compounded BHRT drug products to treat patients, including information about the medical condition(s) that these compounded drug products have been used to treat; 
Describe the physical and chemical characteristics of compounded BHRT drug products (e.g., active ingredient, inactive ingredient(s), dosage forms, routes of administration, strengths); 
Review and assess the available evidence (or lack of evidence) regarding the safety and effectiveness of compounded BHRT drug products; 
Based on the available evidence, summarize findings and make recommendations with respect to 
          - the clinical utility of compounded BHRT drug products; 
          - whether the available evidence of safety and effectiveness supports use of compounded BHRT drug products to treat patients; and 
          - the patient populations that might need a compounded BHRT drug product in lieu of an FDA-approved drug product. 


  • the clinical utility of compounded BHRT drug products;
  • the clinical utility of compounded BHRT drug products;

For more information

 

Sign Up to Receive Email Updates